Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma.

Oosting SF, Haddad RI.

Front Oncol. 2019 Aug 27;9:815. doi: 10.3389/fonc.2019.00815. eCollection 2019. Review.

2.

Evaluating the Utility and Prevalence of HPV Biomarkers in Oral Rinses and Serology for HPV-related Oropharyngeal Cancer.

D'Souza G, Clemens G, Troy T, Castillo RG, Struijk L, Waterboer T, Bender N, Pierorazio PM, Best SR, Strickler H, Wiley DJ, Haddad RI, Posner M, Fakhry C.

Cancer Prev Res (Phila). 2019 Oct;12(10):689-700. doi: 10.1158/1940-6207.CAPR-19-0185. Epub 2019 Aug 16.

PMID:
31420362
3.

Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States.

Mahal BA, Catalano PJ, Haddad RI, Hanna GJ, Kass JI, Schoenfeld JD, Tishler RB, Margalit DN.

Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1660-1667. doi: 10.1158/1055-9965.EPI-19-0038. Epub 2019 Jul 29.

PMID:
31358520
4.

Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer.

Hanna GJ, Lau CJ, Mahmood U, Supplee JG, Mogili AR, Haddad RI, Jänne PA, Paweletz CP.

Oral Oncol. 2019 Aug;95:120-126. doi: 10.1016/j.oraloncology.2019.06.019. Epub 2019 Jun 20.

PMID:
31345379
5.

A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck.

Margalit DN, Haddad RI, Tishler RB, Chau NG, Schoenfeld JD, Bakst RL, Misiukiewicz KJ, Gupta V, Posner M, Hanna GJ, Mahmood U, Rawal B, Catalano PJ, Rath L, Bacay A, McHugh P, Rabinowits G.

Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):132-139. doi: 10.1016/j.ijrobp.2019.04.034. Epub 2019 May 11.

PMID:
31082494
6.

Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.

Kacew AJ, Harris EJ, Lorch JH, Haddad RI, Chau NG, Rabinowits G, LeBoeuf NR, Schmults CD, Thakuria M, MacConaill LE, Hanna GJ.

Eur J Cancer. 2019 May;113:1-9. doi: 10.1016/j.ejca.2019.03.004. Epub 2019 Apr 4.

PMID:
30954880
7.

IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing.

LaVigne AW, Margalit DN, Rawal B, Puzanov M, Annino DJ, Goguen LA, Sher DJ, Schoenfeld JD, Chau NG, Lorch JH, Rabinowits G, Haddad RI, Tishler RB.

Head Neck. 2019 Apr;41(4):959-966. doi: 10.1002/hed.25531. Epub 2019 Jan 8.

PMID:
30620435
8.

Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.

Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V.

Ann Oncol. 2019 Mar 1;30(3):471-477. doi: 10.1093/annonc/mdy549.

PMID:
30596812
9.

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA.

J Natl Compr Canc Netw. 2018 Dec;16(12):1429-1440. doi: 10.6004/jnccn.2018.0089.

PMID:
30545990
10.

Toward a Personalized Approach in the Treatment of Salivary Ductal Carcinoma.

Tsai FD, Haddad RI.

J Natl Compr Canc Netw. 2018 Oct;16(10):1269-1270. doi: 10.6004/jnccn.2018.7089. No abstract available.

PMID:
30323095
11.

Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma.

Sridharan V, Rahman RM, Huang RY, Chau NG, Lorch JH, Uppaluri R, Haddad RI, Hanna GJ, Schoenfeld JD.

Oral Oncol. 2018 Oct;85:29-34. doi: 10.1016/j.oraloncology.2018.08.005. Epub 2018 Aug 17.

PMID:
30220316
12.

Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer.

Hanna GJ, Kacew A, Chau NG, Shivdasani P, Lorch JH, Uppaluri R, Haddad RI, MacConaill LE.

JCI Insight. 2018 Sep 6;3(17). pii: 122799. doi: 10.1172/jci.insight.122799. eCollection 2018 Sep 6.

13.

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM.

Nat Genet. 2018 Sep;50(9):1271-1281. doi: 10.1038/s41588-018-0200-2. Epub 2018 Aug 27.

14.

Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer.

Hanna GJ, Supplee JG, Kuang Y, Mahmood U, Lau CJ, Haddad RI, Jänne PA, Paweletz CP.

Ann Oncol. 2018 Sep 1;29(9):1980-1986. doi: 10.1093/annonc/mdy251.

PMID:
30010779
15.

Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.

Schoenfeld JD, Gjini E, Rodig SJ, Tishler RB, Rawal B, Catalano PJ, Uppaluri R, Haddad RI, Hanna GJ, Chau NG, Rabinowits G, Lorch J, Jo VY, Krane JF, Goguen LA, Annino DJ, Abdelrahman S, Lipschitz M, Margalit DN.

Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):137-145. doi: 10.1016/j.ijrobp.2018.05.002. Epub 2018 Jun 29.

PMID:
29960819
16.

Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.

Ferrarotto R, William WN Jr, Tseng JE, Marur S, Shin DM, Murphy B, Cohen EEW, Thomas CY, Willey R, Cosaert J, Harun N, Jack Lee J, Wistuba IW, Haddad RI, Glisson BS.

Oral Oncol. 2018 Jul;82:83-90. doi: 10.1016/j.oraloncology.2018.05.014. Epub 2018 May 19.

PMID:
29909907
17.

Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors.

Hanna GJ, Kofman ER, Shazib MA, Woo SB, Reardon B, Treister NS, Haddad RI, Cutler CS, Antin JH, Van Allen EM, Uppaluri R, Soiffer RJ.

Oral Oncol. 2018 Jun;81:1-9. doi: 10.1016/j.oraloncology.2018.04.007. Epub 2018 Apr 10.

PMID:
29884406
18.

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2018 May;16(5):479-490. doi: 10.6004/jnccn.2018.0026.

19.

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions.

Haddad RI, Posner M, Hitt R, Cohen EEW, Schulten J, Lefebvre JL, Vermorken JB.

Ann Oncol. 2018 May 1;29(5):1130-1140. doi: 10.1093/annonc/mdy102.

20.

Frameshift events predict anti-PD-1/L1 response in head and neck cancer.

Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, Chau NG, Schoenfeld JD, Lorch JH, Uppaluri R, MacConaill LE, Haddad RI.

JCI Insight. 2018 Feb 22;3(4). pii: 98811. doi: 10.1172/jci.insight.98811. eCollection 2018 Feb 22.

21.

Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.

Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD Jr, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH.

Clin Cancer Res. 2018 Apr 1;24(7):1546-1553. doi: 10.1158/1078-0432.CCR-17-2297. Epub 2018 Jan 4.

22.

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.

Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Krämer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Machiels JH.

Ann Oncol. 2017 Oct 1;28(10):2526-2532. doi: 10.1093/annonc/mdx344.

23.

Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy.

Margalit DN, Schoenfeld JD, Rawal B, Haddad RI, Catalano PJ, Goguen LA, Chau NG, Rabinowits G, Lorch JH, Annino DJ, Tishler RB.

Oral Oncol. 2017 Oct;73:160-165. doi: 10.1016/j.oraloncology.2017.08.012. Epub 2017 Sep 8.

PMID:
28939070
24.

Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer.

Rabinowits G, Bowden M, Flores LM, Verselis S, Vergara V, Jo VY, Chau N, Lorch J, Hammerman PS, Thomas T, Goguen LA, Annino D, Schoenfeld JD, Margalit DN, Tishler RB, Haddad RI.

Front Oncol. 2017 Aug 29;7:191. doi: 10.3389/fonc.2017.00191. eCollection 2017.

25.

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.

26.

Management of elderly patients with locoregionally confined head and neck cancer.

Porceddu SV, Haddad RI.

Lancet Oncol. 2017 May;18(5):e274-e283. doi: 10.1016/S1470-2045(17)30229-2. Epub 2017 Apr 26. Review.

PMID:
28456589
27.

Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma.

Hanna GJ, Sridharan V, Margalit DN, La Follette SK, Chau NG, Rabinowits G, Lorch JH, Haddad RI, Tishler RB, Anderson KS, Schoenfeld JD.

Cancer Biomark. 2017;19(2):129-136. doi: 10.3233/CBM-160071.

PMID:
28387659
28.

Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment.

Zhang Y, Waterboer T, Haddad RI, Miles BA, Wentz A, Gross ND, Fakhry C, Quon H, Lorch JH, Gourin CG, Clayburgh D, Misiukiewicz KJ, Richmon JD, Andersen PE, Posner MR, D'Souza G.

Oral Oncol. 2017 Apr;67:77-82. doi: 10.1016/j.oraloncology.2017.02.004. Epub 2017 Feb 15.

29.

Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck.

Hanna GJ, Liu H, Jones RE, Bacay AF, Lizotte PH, Ivanova EV, Bittinger MA, Cavanaugh ME, Rode AJ, Schoenfeld JD, Chau NG, Haddad RI, Lorch JH, Wong KK, Uppaluri R, Hammerman PS.

Oral Oncol. 2017 Apr;67:61-69. doi: 10.1016/j.oraloncology.2017.02.005. Epub 2017 Feb 14.

PMID:
28351582
30.

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.

Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI.

Endocrine. 2017 Apr;56(1):121-128. doi: 10.1007/s12020-017-1233-5. Epub 2017 Feb 3.

31.

Highlights in Head and Neck Cancer.

Chau NG, Tishler RB, Haddad RI.

JAMA Oncol. 2017 Apr 1;3(4):441-442. doi: 10.1001/jamaoncol.2016.3648. No abstract available.

PMID:
27893016
32.

Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences.

Margalit DN, Rawal B, Catalano PJ, Haddad RI, Goguen LA, Annino DJ, Limaye SA, Lorch JH, Lavigne AW, Schoenfeld JD, Sher DJ, Tishler RB.

Oral Oncol. 2016 Oct;61:19-26. doi: 10.1016/j.oraloncology.2016.07.012. Epub 2016 Aug 6.

PMID:
27688100
33.

Antiangiogenic agents in head and neck squamous cell carcinoma: Tired of going solo.

Chau NG, Haddad RI.

Cancer. 2016 Dec 1;122(23):3592-3595. doi: 10.1002/cncr.30352. Epub 2016 Sep 20. No abstract available.

34.

Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial.

Lu W, Wayne PM, Davis RB, Buring JE, Li H, Macklin EA, Lorch JH, Burke E, Haddad TC, Goguen LA, Rosenthal DS, Tishler RB, Posner MR, Haddad RI.

Oncologist. 2016 Dec;21(12):1522-1529. Epub 2016 Aug 10.

35.

Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck.

Chau NG, Hurwitz S, Mitchell CM, Aserlind A, Grunfeld N, Kaplan L, Hsi P, Bauer DE, Lathan CS, Rodriguez-Galindo C, Tishler RB, Haddad RI, Sallan SE, Bradner JE, French CA.

Cancer. 2016 Dec 1;122(23):3632-3640. doi: 10.1002/cncr.30242. Epub 2016 Aug 10.

36.

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer.

Sridharan V, Margalit DN, Lynch SA, Severgnini M, Zhou J, Chau NG, Rabinowits G, Lorch JH, Hammerman PS, Hodi FS, Haddad RI, Tishler RB, Schoenfeld JD.

Br J Cancer. 2016 Jul 12;115(2):252-60. doi: 10.1038/bjc.2016.166. Epub 2016 Jul 5.

37.

Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients.

Sridharan V, Margalit DN, Lynch SA, Severgnini M, Hodi FS, Haddad RI, Tishler RB, Schoenfeld JD.

J Immunother Cancer. 2016 Jun 21;4:32. doi: 10.1186/s40425-016-0138-9. eCollection 2016.

38.

Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes.

Sridharan V, Gjini E, Liao X, Chau NG, Haddad RI, Severgnini M, Hammerman P, El-Naggar A, Freeman GJ, Hodi FS, Rodig SJ, Dranoff G, Schoenfeld JD.

Cancer Immunol Res. 2016 Aug;4(8):679-87. doi: 10.1158/2326-6066.CIR-16-0031. Epub 2016 Jun 16.

39.

The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium.

Hashim D, Sartori S, Brennan P, Curado MP, Wünsch-Filho V, Divaris K, Olshan AF, Zevallos JP, Winn DM, Franceschi S, Castellsagué X, Lissowska J, Rudnai P, Matsuo K, Morgenstern H, Chen C, Vaughan TL, Hofmann JN, D'Souza G, Haddad RI, Wu H, Lee YC, Hashibe M, Vecchia CL, Boffetta P.

Ann Oncol. 2016 Aug;27(8):1619-25. doi: 10.1093/annonc/mdw224. Epub 2016 May 27.

40.

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.

Clement PM, Gauler T, Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Cohen EE, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Vermorken JB; LUX-H&N 1 investigators.

Ann Oncol. 2016 Aug;27(8):1585-93. doi: 10.1093/annonc/mdw151. Epub 2016 Apr 15.

41.

Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer.

Keane FK, Chen YH, Tishler RB, Schoenfeld JD, Haddad RI, Goguen LA, Catalano P, Neville BA, Margalit DN.

Head Neck. 2016 Oct;38(10):1530-8. doi: 10.1002/hed.24470. Epub 2016 Apr 15.

PMID:
27080700
42.

Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.

Chau NG, Li YY, Jo VY, Rabinowits G, Lorch JH, Tishler RB, Margalit DN, Schoenfeld JD, Annino DJ, Goguen LA, Thomas T, Becker H, Haddad T, Krane JF, Lindeman NI, Shapiro GI, Haddad RI, Hammerman PS.

Clin Cancer Res. 2016 Jun 15;22(12):2939-49. doi: 10.1158/1078-0432.CCR-15-2314. Epub 2016 Jan 13.

43.

Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience.

Lorch JH, Hanna GJ, Posner MR, O'Neill A, Thotakura VL, Limaye SA, Rabinowits G, Sher DJ, Tishler RB, Haddad RI.

Head Neck. 2016 Apr;38 Suppl 1:E1618-24. doi: 10.1002/hed.24289. Epub 2015 Nov 28.

PMID:
26614576
44.

Sequential and Concurrent Chemoradiation: State of the Art.

Chau NG, Haddad RI.

Hematol Oncol Clin North Am. 2015 Dec;29(6):1061-74. doi: 10.1016/j.hoc.2015.07.005. Epub 2015 Oct 21. Review.

PMID:
26568548
45.

Anaplastic Thyroid Carcinoma, Version 2.2015.

Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McCaffrey JC, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Hoffmann KG, Hughes M.

J Natl Compr Canc Netw. 2015 Sep;13(9):1140-50.

46.

Optimizing Tobacco Cessation Resource Awareness Among Patients and Providers.

Ma L, Donohue C, DeNofrio T, Vitale Pedulla L, Haddad RI, Rabinowits G.

J Oncol Pract. 2016 Jan;12(1):e77-82. doi: 10.1200/JOP.2015.005124. Epub 2015 Sep 1.

PMID:
26330532
47.

Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium.

Boffetta P, Hayes RB, Sartori S, Lee YC, Muscat J, Olshan A, Winn DM, Castellsagué X, Zhang ZF, Morgenstern H, Chen C, Schwartz SM, Vaughan TL, Wunsch-Filho V, Purdue M, Koifman S, Curado MP, Vilensky M, Gillison M, Fernandez L, Menezes A, Daudt AW, Schantz S, Yu G, D'Souza G, Haddad RI, La Vecchia C, Hashibe M.

Eur J Cancer Prev. 2016 Jul;25(4):344-8. doi: 10.1097/CEJ.0000000000000179.

48.

Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma.

Rettig EM, Wentz A, Posner MR, Gross ND, Haddad RI, Gillison ML, Fakhry C, Quon H, Sikora AG, Stott WJ, Lorch JH, Gourin CG, Guo Y, Xiao W, Miles BA, Richmon JD, Andersen PE, Misiukiewicz KJ, Chung CH, Gerber JE, Rajan SD, D'Souza G.

JAMA Oncol. 2015 Oct;1(7):907-15. doi: 10.1001/jamaoncol.2015.2524.

PMID:
26226294
49.

Head and Neck Cancers, Version 1.2015.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M.

J Natl Compr Canc Netw. 2015 Jul;13(7):847-55; quiz 856.

50.

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators.

Lancet Oncol. 2015 May;16(5):583-94. doi: 10.1016/S1470-2045(15)70124-5. Epub 2015 Apr 16.

PMID:
25892145

Supplemental Content

Loading ...
Support Center